441 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AZN Astrazeneca PLC $37.56 $95.16B N/A
Article Searches
Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression http://www.zacks.com/stock/news/421714/allergans-agn-vraylar-gets-fda-nod-for-bipolar-depression?cid=CS-ZC-FT-421714 May 29, 2019 - Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.
Novartis Gets FDA Nod for Breast Cancer Drug & Gene Therapy http://www.zacks.com/stock/news/420120/novartis-gets-fda-nod-for-breast-cancer-drug-gene-therapy?cid=CS-ZC-FT-420120 May 27, 2019 - Novartis (NVS) obtains FDA approvals for a breast cancer drug and a gene therapy for pediatric patients.
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark http://www.zacks.com/stock/news/412897/aveo-pharmaceuticals-aveo-q1-earnings-revenues-miss-mark?cid=CS-ZC-FT-412897 May 11, 2019 - AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark http://www.zacks.com/stock/news/412859/aveo-pharmaceuticals-aveo-q1-earnings-revenues-miss-mark?cid=CS-ZC-FT-412859 May 10, 2019 - AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug http://www.zacks.com/stock/news/412433/pharma-stock-roundup-agn-nvo-report-q1-earnings-nvs-to-buy-takedas-eye-drug?cid=CS-ZC-FT-412433 May 10, 2019 - Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up? http://www.zacks.com/stock/news/406072/aveo-pharmaceuticals-aveo-to-post-q1-earnings-whats-up?cid=CS-ZC-FT-406072 Apr 30, 2019 - During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.
Better Big Pharma Stock: AbbVie vs. AstraZeneca https://www.fool.com/investing/2019/04/29/better-big-pharma-stock-abbvie-vs-astrazeneca.aspx?source=iedfolrf0000001 Apr 29, 2019 - These A-list drugmakers must both contend with expiring patents, new drug uncertainties, and hungry competitors. But they're in different stages of their cyclical journeys.
AstraZeneca PLC (AZN) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/04/26/astrazeneca-plc-azn-q1-2019-earnings-call-transcri.aspx?source=iedfolrf0000001 Apr 26, 2019 - AZN earnings call for the period ending March 31, 2019.
AstraZeneca PLC (AZN) CEO Pascal Soriot on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4257301-astrazeneca-plc-azn-ceo-pascal-soriot-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare Apr 26, 2019 - AstraZeneca PLC (NYSE:AZN) Q1 2019 Earnings Conference Call April 26, 2019, 07:00 ET Company Participants Pascal Soriot - CEO & Executive Director David Fredrickson - EVP & President, Oncology
AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales http://www.zacks.com/stock/news/404479/astrazenecas-azn-q1-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-404479 Apr 26, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the first quarter. New drugs, especially cancer drugs, drive revenues.

Pages: 1234567...45

<Page 2>